Clinical trials: Oral Cancers
Pain
Pharmacokinetics & Safety of Diclofenac Potassium Oral Solution in Ped. Subjects (2-12 Yrs) With Mild-Mod. Acute Pain
As part of the Pediatric Research Equity Act (PREA) commitment, the objectives of the study are to characterize the pharmacokinetic (PK) profile and to determine the safety and tolerability of diclofenac potassium oral solution…
- Trial name
- NCT02287350
- Testing
- diclofenac potassium oral solution
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Depomed
Acute Myeloid Leukemia
A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
This is a multicenter, prospective, non-randomized, Phase I-II trial to assess the efficacy and safety of the combination of oral quizartinib and FLAG-IDA chemotherapy schedule (FLAG-QUIDA regimen) in first relapsed/refractory…
- Trial name
- NCT04112589
- Testing
- Quizartinib, Fludarabine, Cytarabine
- Where
- 20 sites in Spain
- Volunteers
- 63 people
- Sponsor
- PETHEMA Foundation
Colorectal Cancer
Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005050
- Testing
- ethynyluracil, fluorouracil, oxaliplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Colorectal Cancer, Esophageal Cancer
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00019513
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Oral Cancer
Different Modalities Flaps of Head and Neck Reconstructions in Oral Cancer Patients
Different Modalities of Flaps used in Head and Neck Reconstructions in oral cancer Patients, retrospective study Study design: This study will be conducted in a Retrospective study with prospective collective data.
- Trial name
- NCT07143058
- Testing
- Flaps reconstruction in head and neck in oral cance, Flap of head and neck
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ahmed Mohamed Abdelhafiz
Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
A Window of Opportunity Study of Black Raspberry for Patients With HNSCC
The purpose of this phase 0 Window of Opportunity study is to have subjects with Head and Neck Squamous Cell Carcinoma (HNSCC) receive same dosage of Black Raspberry Extract between their cancer diagnosis and standard treatment…
- Trial name
- NCT06086925
- Testing
- Black Raspberry
- Sponsor
- Mitchell Machtay
Preoperative, Sleep Disturbance
Preoperative Oral Midazolam to Postoperative Pain Relief in Sleep Disturbance or Anxiety Patients With Colorectal Cancer
Previous studies have indicated a high incidence of sleep disturbances and anxiety symptoms in individuals with colorectal cancers prior to undergoing surgery, leading to worsened postoperative pain, slower recovery, and higher…
- Conditions
- Preoperative, Sleep Disturbance, Anxiety, Midazolam
- Trial name
- POMPPR (NCT06407518)
- Testing
- Midazolam oral solution
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Nasopharyngeal Carcinoma, Dysphagia
Intermittent Oral-esophageal Tube Feeding in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma
This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for NPC. Patients enrolled are randomly divided equally into the observation group and the control group.
- Trial name
- NPC (NCT06189482)
- Testing
- Intermittent Oral-esophageal Tube Feeding, nasogastric tube feeding
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Zeng Changhao
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
- Trial name
- NCT00023959
- Testing
- hydroxyurea, fluorouracil, bevacizumab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Myelofibrosis, Myeloproliferative Disorders
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
The study consists of two phases: The first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once daily…
- Conditions
- Myelofibrosis, Myeloproliferative Disorders, Polycythemia Vera, Essential Thrombocythemia
- Trial name
- NCT00745550
- Testing
- SB1518
- Where
- 6 sites in United States, Australia
- Volunteers
- 55 people
- Sponsor
- S*BIO
Mucositis
Phase 2a Study to Evaluate Suppression of Methotrexate-induced Mucositis by TK112690
Patients will receive methotrexate at a dose of 45 mg/m2 administered weekly for 4 consecutive weeks as an iv infusion along with a nutritional supplement administered two hours before the methotrexate.
- Trial name
- TK112690 (NCT04046250)
- Testing
- TK-112690
- Where
- 3 sites in India
- Volunteers
- 22 people
- Sponsor
- Tosk, Inc.
Colorectal Cancer, Lung Cancer
AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)
RATIONALE: AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Colorectal Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00107250
- Testing
- capecitabine, carboplatin, cediranib maleate
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- NCIC Clinical Trials Group
Solid Tumor, Adult
The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol
This is multicenter, open-label, 2-part crossover study. Eligible subjects will have metastatic or unresectable solid tumors. This study includes a pretreatment and treatment phase.
- Trial name
- NCT03892018
- Testing
- Oraxol
- Where
- 3 sites in United Kingdom
- Volunteers
- 29 people
- Sponsor
- Athenex, Inc.
Non-small Cell Lung Cancer Metastatic
Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC
Title: Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC. A phase IV study.
- Trial name
- VIVOS (NCT01848613)
- Testing
- Vinorelbine
- Where
- 8 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
This clinical trial studies how well intensity modulated proton therapy (IMPT) or intensity modulated X-ray (radiation) therapy (IMRT) works after surgery in treating patients with head and neck cancer.
- Conditions
- Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary, Hypopharyngeal Carcinoma, Laryngeal Carcinoma
- Trial name
- NCT05075980
- Testing
- Cisplatin, Intensity-Modulated Proton Therapy, Quality-of-Life Assessment
- Where
- 9 sites in United States
- Volunteers
- 174 people
- Sponsor
- Mayo Clinic
Head and Neck Squamous Cell Carcinoma
Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer
The investigators designed a prospective randomized double-blind trial to determine if the oral immunomodulating formula could improve the disease-free survival rate in high-risk locally-advanced head and neck Squamous Cell…
- Trial name
- SIMPA01 (NCT04001543)
- Testing
- Immunomodulating oral supplementation, Sip feed control
- Where
- 2 sites in France
- Volunteers
- 27 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Medullary Thyroid Cancer
Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib
Study in healthy volunteers to assess effect of omeprazole and ranitidine on the pharmacokinetics of vandetanib
- Trial name
- Vandetanib (NCT01539655)
- Testing
- vandetanib, omeprazole, ranitidine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sanofi
Head and Neck Cancer
Gene Expression Profiles in Predicting Survival of Patients With Head and Neck Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897052
- Testing
- microarray analysis, laboratory biomarker analysis
- Volunteers
- 29 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Advanced Solid Tumor Cancers, Medulloblastoma
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma
- Trial name
- NCT00880308
- Testing
- LDE225
- Where
- 5 sites in United States, Spain and 2 more
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Sarcoma, Soft Tissue
Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma
This is a prospective, multicentric, randomized, open label Phase II trial investigating whether the oral angiogenesis inhibitor nintedanib, as compared to the intravenous cytotoxic compound ifosfamide, given for patients with…
- Trial name
- ANITA (NCT02808247)
- Testing
- Nintedanib, Ifosfamide
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 80 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC